{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:23:25Z","timestamp":1793114605350,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Science & Technology Pillar Program during the Twelfth Five-year Plan Period","award":["2014BAI09B10"],"award-info":[{"award-number":["2014BAI09B10"]}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2017A030312003"],"award-info":[{"award-number":["2017A030312003"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81572658"],"award-info":[{"award-number":["81572658"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012176","name":"Program of Introducing Talents of Discipline to Universities","doi-asserted-by":"crossref","award":["B14035"],"award-info":[{"award-number":["B14035"]}],"id":[{"id":"10.13039\/501100012176","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Innovation Team Development Plan of the Ministry of Education","award":["No. IRT_17R110"],"award-info":[{"award-number":["No. IRT_17R110"]}]},{"name":"Guangzhou key medical discipline construction project fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-5177-9","type":"journal-article","created":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T14:03:21Z","timestamp":1545228201000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma"],"prefix":"10.1186","volume":"18","author":[{"given":"Jian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Zhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Hua","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,19]]},"reference":[{"key":"5177_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"5177_CR2","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40880-017-0257-9","volume":"36","author":"KR Wei","year":"2017","unstructured":"Wei KR, Zheng RS, Zhang SW, et al. Nasopharyngeal carcinoma incidence and mortality in China, 2013. Chin J Cancer. 2017;36:90.","journal-title":"Chin J Cancer"},{"key":"5177_CR3","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","volume":"16","author":"M Al-Sarraf","year":"1998","unstructured":"Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol. 1998;16:1310\u20137.","journal-title":"J Clin Oncol"},{"key":"5177_CR4","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2003.06.158","volume":"21","author":"JC Lin","year":"2003","unstructured":"Lin JC, Jan JS, Hsu CY, et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. 2003;21:631\u20137.","journal-title":"J Clin Oncol"},{"key":"5177_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ijrobp.2005.12.003","volume":"65","author":"JL Yi","year":"2006","unstructured":"Yi JL, Gao L, Huang XD, et al. Nasopharyngeal carcinoma treated by radical radiotherapy alone: ten-year experience of a single institution. Int J Radiat Oncol Biol Phys. 2006;65:161\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5177_CR6","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ijrobp.2010.03.024","volume":"80","author":"SZ Lai","year":"2011","unstructured":"Lai SZ, Li WF, Chen L, et al. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys. 2011;80:661\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5177_CR7","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1200\/JCO.2001.19.23.4305","volume":"19","author":"RL Hong","year":"2001","unstructured":"Hong RL, Ting LL, Ko JY, et al. Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol. 2001;19:4305\u201313.","journal-title":"J Clin Oncol"},{"key":"5177_CR8","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.2008.18.1545","volume":"27","author":"EP Hui","year":"2009","unstructured":"Hui EP, Ma BB, Leung SF, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol. 2009;27:242\u20139.","journal-title":"J Clin Oncol"},{"key":"5177_CR9","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s00280-010-1399-5","volume":"67","author":"M Airoldi","year":"2011","unstructured":"Airoldi M, Gabriele P, Gabriele AM, et al. Induction chemotherapy with carboplatin and taxol followed by radiotherapy and concurrent weekly carboplatin + taxol in locally advanced nasopharyngeal carcinoma. Cancer Chemoth Pharm. 2011;67:1027\u201334.","journal-title":"Cancer Chemoth Pharm"},{"key":"5177_CR10","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.2147\/OTT.S133917","volume":"10","author":"XW Lan","year":"2017","unstructured":"Lan XW, Xiao Y, Zou XB, et al. Outcomes of adding induction chemotherapy to concurrent chemoradiotherapy for stage T3N0-1 nasopharyngeal carcinoma: a propensity-matched study. Onco Targets Ther. 2017;10:3853\u201360.","journal-title":"Onco Targets Ther"},{"key":"5177_CR11","doi-asserted-by":"crossref","first-page":"76807","DOI":"10.18632\/oncotarget.20014","volume":"8","author":"LR Wu","year":"2017","unstructured":"Wu LR, Yu HL, Jiang N, et al. Prognostic value of chemotherapy in addition to concurrent chemoradiotherapy in T3-4N0-1 nasopharyngeal carcinoma: a propensity score matching study. Oncotarget. 2017;8:76807\u201315.","journal-title":"Oncotarget"},{"key":"5177_CR12","unstructured":"Tang LQ, Li CF, Li J, et al. Establishment and validation of prognostic nomograms for endemic nasopharyngeal carcinoma. J Natl Cancer Inst. 2016;108."},{"key":"5177_CR13","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1056\/NEJMoa032260","volume":"350","author":"JC Lin","year":"2004","unstructured":"Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004;350:2461\u201370.","journal-title":"N Engl J Med"},{"key":"5177_CR14","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.clon.2010.09.001","volume":"23","author":"X Hou","year":"2011","unstructured":"Hou X, Zhao C, Guo Y, et al. Different clinical significance of pre- and post-treatment plasma Epstein-Barr virus DNA load in nasopharyngeal carcinoma treated with radiotherapy. Clin Oncol. 2011;23:128\u201333.","journal-title":"Clin Oncol"},{"key":"5177_CR15","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1093\/annonc\/mdu117","volume":"25","author":"SF Leung","year":"2014","unstructured":"Leung SF, Chan KC, Ma BB, et al. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Ann Oncol. 2014;25:1204\u20138.","journal-title":"Ann Oncol"},{"key":"5177_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijrobp.2014.01.052","volume":"89","author":"CW Twu","year":"2014","unstructured":"Twu CW, Wang WY, Chen CC, et al. Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid. Int J Radiat Oncol Biol Phys. 2014;89:21\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5177_CR17","doi-asserted-by":"crossref","first-page":"29739","DOI":"10.18632\/oncotarget.8828","volume":"7","author":"SS Guo","year":"2016","unstructured":"Guo SS, Tang LQ, Chen QY, et al. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA >\/=4000 copies\/ml: a matched study. Oncotarget. 2016;7:29739\u201348.","journal-title":"Oncotarget"},{"key":"5177_CR18","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.7150\/jca.15736","volume":"7","author":"H Peng","year":"2016","unstructured":"Peng H, Chen L, Li WF, et al. Prognostic value of neoadjuvant chemotherapy in Locoregionally advanced nasopharyngeal carcinoma with low pre-treatment Epstein-Barr virus DNA: a propensity-matched analysis. J Cancer. 2016;7:1465\u201371.","journal-title":"J Cancer"},{"key":"5177_CR19","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1002\/cncr.30775","volume":"123","author":"JW Lv","year":"2017","unstructured":"Lv JW, Chen YP, Huang XD, et al. Hepatitis B virus screening and reactivation and management of patients with nasopharyngeal carcinoma: a large-scale, big-data intelligence platform-based analysis from an endemic area. Cancer. 2017;123:3540\u20139.","journal-title":"Cancer"},{"key":"5177_CR20","first-page":"4059","volume":"24","author":"JY Shao","year":"2004","unstructured":"Shao JY, Zhang Y, Li YH, et al. Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma. Anticancer Res. 2004;24:4059\u201366.","journal-title":"Anticancer Res"},{"key":"5177_CR21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.radonc.2015.07.030","volume":"116","author":"YP Chen","year":"2015","unstructured":"Chen YP, Sun Y, Chen L, et al. Surrogate endpoints for overall survival in combined chemotherapy and radiotherapy trials in nasopharyngeal carcinoma: meta-analysis of randomised controlled trials. Radiother Oncol. 2015;116:157\u201366.","journal-title":"Radiother Oncol"},{"key":"5177_CR22","doi-asserted-by":"crossref","unstructured":"Rotolo F, Pignon JP, Bourhis J, et al. Surrogate end points for overall survival in loco-regionally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis. J Natl Cancer Inst. 2017;109.","DOI":"10.1093\/jnci\/djw239"},{"key":"5177_CR23","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.radonc.2013.10.020","volume":"110","author":"X Sun","year":"2014","unstructured":"Sun X, Su S, Chen C, et al. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol. 2014;110:398\u2013403.","journal-title":"Radiother Oncol"},{"key":"5177_CR24","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.ijrobp.2004.05.022","volume":"60","author":"MK Kam","year":"2004","unstructured":"Kam MK, Teo PM, Chau RM, et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Int J Radiat Oncol Biol Phys. 2004;60:1440\u201350.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5177_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ijrobp.2005.06.037","volume":"64","author":"B Baujat","year":"2006","unstructured":"Baujat B, Audry H, Bourhis J, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys. 2006;64:47\u201356.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5177_CR26","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ejca.2017.01.002","volume":"75","author":"L Chen","year":"2017","unstructured":"Chen L, Hu CS, Chen XZ, et al. Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase 3 multicentre randomised controlled trial. Eur J Cancer. 2017;75:150\u20138.","journal-title":"Eur J Cancer"},{"key":"5177_CR27","doi-asserted-by":"crossref","unstructured":"Frikha M, Auperin A, Tao Y, et al. A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02). Ann Oncol. 2018;29:731-6.","DOI":"10.1093\/annonc\/mdx770"},{"key":"5177_CR28","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","volume":"17","author":"Y Sun","year":"2016","unstructured":"Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17:1509\u201320.","journal-title":"Lancet Oncol"},{"key":"5177_CR29","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.ijrobp.2015.01.002","volume":"91","author":"T Tan","year":"2015","unstructured":"Tan T, Lim WT, Fong KW, et al. Concurrent chemo-radiation with or without induction gemcitabine, carboplatin, and paclitaxel: a randomized, phase 2\/3 trial in locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2015;91:952\u201360.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5177_CR30","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/nrc1452","volume":"4","author":"LS Young","year":"2004","unstructured":"Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer. 2004;4:757\u201368.","journal-title":"Nat Rev Cancer"},{"key":"5177_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/978-3-642-38965-8_2","volume":"193","author":"CJ Chen","year":"2014","unstructured":"Chen CJ, Hsu WL, Yang HI, et al. Epidemiology of virus infection and human cancer. Recent Results Cancer Res. 2014;193:11\u201332.","journal-title":"Recent Results Cancer Res"},{"key":"5177_CR32","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1093\/jnci\/94.21.1614","volume":"94","author":"AT Chan","year":"2002","unstructured":"Chan AT, Lo YM, Zee B, et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst. 2002;94:1614\u20139.","journal-title":"J Natl Cancer Inst"},{"key":"5177_CR33","first-page":"5452","volume":"59","author":"YM Lo","year":"1999","unstructured":"Lo YM, Chan LY, Chan AT, et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res. 1999;59:5452\u20135.","journal-title":"Cancer Res"},{"key":"5177_CR34","doi-asserted-by":"publisher","first-page":"22000","DOI":"10.1038\/srep22000","volume":"6","author":"H Peng","year":"2016","unstructured":"Peng H, Guo R, Chen L, et al. Prognostic impact of plasma Epstein-Barr virus DNA in patients with nasopharyngeal carcinoma treated using intensity-modulated radiation therapy. Sci Rep. 2016;6:22000.","journal-title":"Sci Rep"},{"key":"5177_CR35","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1016\/j.ejca.2013.03.008","volume":"49","author":"XB Wan","year":"2013","unstructured":"Wan XB, Wei L, Li H, et al. High pretreatment serum lactate dehydrogenase level correlates with disease relapse and predicts an inferior outcome in locally advanced nasopharyngeal carcinoma. Eur J Cancer. 2013;49:2356\u201364.","journal-title":"Eur J Cancer"},{"key":"5177_CR36","doi-asserted-by":"publisher","first-page":"e359","DOI":"10.1016\/j.ijrobp.2011.06.1967","volume":"82","author":"GQ Zhou","year":"2012","unstructured":"Zhou GQ, Tang LL, Mao YP, et al. Baseline serum lactate dehydrogenase levels for patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma: a predictor of poor prognosis and subsequent liver metastasis. Int J Radiat Oncol Biol Phys. 2012;82:e359\u201365.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5177_CR37","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.radonc.2012.09.001","volume":"104","author":"R Guo","year":"2012","unstructured":"Guo R, Sun Y, Yu XL, et al. Is primary tumor volume still a prognostic factor in intensity modulated radiation therapy for nasopharyngeal carcinoma? Radiother Oncol. 2012;104:294\u20139.","journal-title":"Radiother Oncol"},{"key":"5177_CR38","doi-asserted-by":"publisher","first-page":"664","DOI":"10.7150\/jca.14183","volume":"7","author":"XJ Du","year":"2016","unstructured":"Du XJ, Tang LL, Mao YP, et al. Circulating EBV DNA, globulin and nodal size predict distant metastasis after intensity-modulated radiotherapy in stage II nasopharyngeal carcinoma. J Cancer. 2016;7:664\u201370.","journal-title":"J Cancer"},{"key":"5177_CR39","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1158\/1078-0432.CCR-12-3702","volume":"19","author":"QT Le","year":"2013","unstructured":"Le QT, Zhang Q, Cao H, et al. An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma. Clin Cancer Res. 2013;19:2208\u201315.","journal-title":"Clin Cancer Res"},{"key":"5177_CR40","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1177\/0272989X09341755","volume":"29","author":"PC Austin","year":"2009","unstructured":"Austin PC. The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies. Med Decis Mak. 2009;29:661\u201377.","journal-title":"Med Decis Mak"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5177-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-5177-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5177-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T06:44:03Z","timestamp":1605681843000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-5177-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["5177"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-5177-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"16 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written Informed consent was obtained from all patients before treatment and this study was approved by the institutional research ethics committee of Sun Yat-sen University Cancer Center.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"1276"}}